In partnership with Performance Food Group, Pairwise’s Conscious Foods brand will be the first food made with CRISPR technology in the U.S. marketDURHAM, N.C.--(BUSINESS WIRE)--Pairwise, a pioneering food startup, announced today the launch of its inau
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB : DVHGF), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical
Visit exhibit 106 to learn how Covalon is leading the charge with compassion driven innovation through gentler infection prevention solutionsMISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX:
--Poster session at ASGCT meeting describes key progress with shielded CD45 cells--CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) announced today that Mr. Ken Seitz, Nutrien’s President and Chief Executive Officer, will be speaking at the BMO Farm to Market Conference on Wednesday, May 17 at 8:00 a.m. EDT.
Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including
Juno will bring a much-needed expanded offering of critical pharmaceuticals to Canada, by investing in domestic productionTORONTO--(BUSINESS WIRE)--Today, Juno Pharmaceuticals Canada (“Juno”), a leader in the commercialization of specialty pharmaceut
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Mara Renewables Corporation (Mara) is delighted to announce they have made the Sustainable Development Technology Canada (SDTC) Canada’s Sustainability Changemakers list for 2023. The list is comprised of the top t
PARSIPPANY, N.J. & OAKVILLE, Ontario--(BUSINESS WIRE)--Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin)
Received a positive response from the Canada Revenue Agency (the “CRA”) to our Notices of Objection regarding the Harmonized Sales Tax (“HST”) matter previously disclosed in our financial statements The CRA has provided updated Notices of Reass
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.